UBS Group
VIRX

UBS Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

UBS Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11
Closed -$6K – 9490
2014
Q4 		$6K Buy
+11
New +$4.96K ﹤0.01% 8867

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

UBS Group's VIRX Position: Q1 2025 in Review

UBS Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 93,177 shares — an estimated $15K sold.

UBS Group first reported a position in VIRX in Q4 2014 and held it in 38 quarters. The position peaked at $876K in Q4 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • UBS Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 93,177 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $15K.
  • UBS Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 38 quarters.
  • UBS Group's Viracta Therapeutics, Inc. Common Stock position peaked at $876K in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.